(GL9) Glanbia - IR
Sector: Consumer Defensive | Industry: Packaged Foods | Exchange: IR (Ireland) | Market Cap: 5.245m EUR | Total Return: 72% in 12m
Avg Turnover: 12.7M
Rev. Trend: -82.8%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Shakeout, Supp Ema20, Rs Leader, Idiosyncratic Leader, Tailwind
Glanbia plc is an Ireland-based global nutrition company specializing in sports and lifestyle supplements, dairy-based ingredients, and functional premixes. Its portfolio includes market-leading brands such as Optimum Nutrition and BSN, which are distributed through specialized retail, e-commerce, and mass-market channels.
The company operates a vertically integrated business model, leveraging its origins in dairy processing to produce high-value whey protein isolates and bioactive ingredients for the broader food and beverage industry. The sports nutrition sector is characterized by high brand loyalty and a shift toward ready-to-drink (RTD) and ready-to-eat (RTE) formats to meet consumer demand for convenience.
Investors can further examine the companys valuation metrics and historical performance on ValueRay. Beyond its core nutrition focus, Glanbia maintains diversified interests in property dealing, financing, and business management solutions.
- Glanbia Performance Nutrition volume growth driven by Optimum Nutrition brand scaling
- Raw material price volatility impacts Glanbia Nutritionals segment margins
- Strategic acquisitions and divestitures accelerate shift toward high-margin branded nutrition
- US consumer spending trends influence demand for premium protein and lifestyle products
| Net Income: 365.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -2.05 > 1.0 |
| NWC/Revenue: 8.01% < 20% (prev 7.90%; Δ 0.11% < -1%) |
| CFO/TA 0.09 > 3% & CFO 368.5m > Net Income 365.0m |
| Net Debt (-382.7m) to EBITDA (575.9m): -0.66 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (242.5m) vs 12m ago -8.58% < -2% |
| Gross Margin: 24.40% > 18% (prev 17.37%; Δ 7.04% > 0.5%) |
| Asset Turnover: 137.9% > 50% (prev 141.3%; Δ -3.39% > 0%) |
| Interest Coverage Ratio: 14.29 > 6 (EBIT TTM 417.2m / Interest Expense TTM 29.2m) |
| A: 0.11 (Total Current Assets 1.65b - Total Current Liabilities 1.22b) / Total Assets 3.97b |
| B: 0.41 (Retained Earnings 1.61b / Total Assets 3.97b) |
| C: 0.11 (EBIT TTM 417.2m / Avg Total Assets 3.92b) |
| D: 0.94 (Book Value of Equity 1.93b / Total Liabilities 2.05b) |
| Altman-Z'' = 3.74 = AA |
| DSRI: 1.16 (Receivables 381.3m/331.7m, Revenue 5.41b/5.48b) |
| GMI: 0.71 (GM 17.37% / 24.40%) |
| AQI: 0.94 (AQ_t 0.43 / AQ_t-1 0.46) |
| SGI: 0.99 (Revenue 5.41b / 5.48b) |
| TATA: -0.00 (NI 365.0m - CFO 368.5m) / TA 3.97b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of June 16, 2026, the stock is trading at EUR 21.70 with a total of 517,062 shares traded.
Over the past week, the price has changed by +1.97%,
over one month by +6.48%,
over three months by +26.88% and
over the past year by +71.95%.
Glanbia has no consensus analysts rating.
Market Cap USD = 6.08b (5.24b EUR * 1.1597 EUR.USD)
P/E Trailing = 34.4444
P/E Forward = 17.1233
P/S = 1.329
P/B = 3.1763
P/EG = 9.0382
Revenue TTM = 5.41b USD
EBIT TTM = 417.2m USD
EBITDA TTM = 575.9m USD
Long Term Debt = 641.6m USD (from longTermDebt, last quarter)
Short Term Debt = 375.6m USD (from shortLongTermDebt, last quarter)
Debt = 108.5m USD (Leases only: 108.5m)
Net Debt = -382.7m USD (calculated: Debt 108.5m - CCE 491.2m)
Enterprise Value = 5.70b USD (6.08b + Debt 108.5m - CCE 491.2m)
Interest Coverage Ratio = 14.29 (Ebit TTM 417.2m / Interest Expense TTM 29.2m)
EV/FCF = 20.09x (Enterprise Value 5.70b / FCF TTM 283.7m)
FCF Yield = 4.98% (FCF TTM 283.7m / Enterprise Value 5.70b)
FCF Margin = 5.24% (FCF TTM 283.7m / Revenue TTM 5.41b)
Net Margin = 6.74% (Net Income TTM 365.0m / Revenue TTM 5.41b)
Gross Margin = 24.40% ((Revenue TTM 5.41b - Cost of Revenue TTM 4.09b) / Revenue TTM)
Gross Margin QoQ = 33.30% (prev 33.30%)
Tobins Q-Ratio = 1.43 (Enterprise Value 5.70b / Total Assets 3.97b)
Interest Expense / Debt = 26.91% (Interest Expense 29.2m / Debt 108.5m)
Taxrate = 13.70% (56.9m / 414.9m)
NOPAT = 360.0m (EBIT 417.2m * (1 - 13.70%))
Current Ratio = 1.36 (Total Current Assets 1.65b / Total Current Liabilities 1.22b)
Debt / Equity = 0.06 (Debt 108.5m / totalStockholderEquity, last quarter 1.93b)
Debt / EBITDA = -0.66 (Net Debt -382.7m / EBITDA 575.9m)
Debt / FCF = -1.35 (Net Debt -382.7m / FCF TTM 283.7m)
Total Stockholder Equity = 2.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.30% (Net Income 365.0m / Total Assets 3.97b)
RoE = 18.12% (Net Income TTM 365.0m / Total Stockholder Equity 2.01b)
RoCE = 15.71% (EBIT 417.2m / Capital Employed (Equity 2.01b + L.T.Debt 641.6m))
RoIC = 14.49% (NOPAT 360.0m / Invested Capital 2.48b)
WACC = 7.39% (E(6.08b)/V(6.19b) * Re(7.11%) + D(108.5m)/V(6.19b) * Rd(26.91%) * (1-Tc(0.14)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -83.55 | Cagr: -4.45%
[DCF] Terminal Value 73.10% ; FCFF base≈312.7m ; Y1≈274.2m ; Y5≈221.5m
[DCF] Fair Price = 16.30 (EV 3.56b - Net Debt -382.7m = Equity 3.94b / Shares 241.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
Revenue Correlation: -82.82 | Revenue CAGR: -14.71% | SUE: 1.22 | # QB: 1
EPS current Year (2026-12-31): EPS=1.49 | Chg30d=+0.45% | Revisions=+43% | GrowthEPS=+10.2% | GrowthRev=+3.2%
EPS next Year (2027-12-31): EPS=1.59 | Chg30d=+0.16% | Revisions=+43% | GrowthEPS=+7.1% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: +43%